These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 23852452)

  • 1. In situ sequencing for RNA analysis in preserved tissue and cells.
    Ke R; Mignardi M; Pacureanu A; Svedlund J; Botling J; Wählby C; Nilsson M
    Nat Methods; 2013 Sep; 10(9):857-60. PubMed ID: 23852452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outlier kinase expression by RNA sequencing as targets for precision therapy.
    Kothari V; Wei I; Shankar S; Kalyana-Sundaram S; Wang L; Ma LW; Vats P; Grasso CS; Robinson DR; Wu YM; Cao X; Simeone DM; Chinnaiyan AM; Kumar-Sinha C
    Cancer Discov; 2013 Mar; 3(3):280-93. PubMed ID: 23384775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.
    Bauer MA; Chavan SS; Peterson EA; Heuck CJ; Johann DJ
    BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S3. PubMed ID: 25350881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
    Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
    Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
    Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
    Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
    King CR; Swain SM; Porter L; Steinberg SM; Lippman ME; Gelmann EP
    Cancer Res; 1989 Aug; 49(15):4185-91. PubMed ID: 2568168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
    Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
    Cancer Med; 2015 Mar; 4(3):392-403. PubMed ID: 25594743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Standardization of evaluation for target molecule in cancer therapy].
    Ochiai A
    Gan To Kagaku Ryoho; 2011 May; 38(5):709-14. PubMed ID: 21566428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
    Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
    Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
    Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
    BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
    Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly multiplexed subcellular RNA sequencing in situ.
    Lee JH; Daugharthy ER; Scheiman J; Kalhor R; Yang JL; Ferrante TC; Terry R; Jeanty SS; Li C; Amamoto R; Peters DT; Turczyk BM; Marblestone AH; Inverso SA; Bernard A; Mali P; Rios X; Aach J; Church GM
    Science; 2014 Mar; 343(6177):1360-3. PubMed ID: 24578530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
    Mincione G; Piccirelli A; Lazzereschi D; Salomon DS; Colletta G
    J Cell Physiol; 1998 Aug; 176(2):383-91. PubMed ID: 9648926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
    Stella GM; Scabini R; Inghilleri S; Cemmi F; Corso S; Pozzi E; Morbini P; Valentini A; Dore R; Ferrari S; Luisetti M; Zorzetto M
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1327-35. PubMed ID: 23644698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.
    Boissière-Michot F; Denouël A; Boulle N; Guillaume C; Orsetti B; Lopez-Crapez E; Chateau MC; Bibeau F
    Pathol Oncol Res; 2013 Jan; 19(1):41-53. PubMed ID: 22893391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of KRAS mutations: evolution or revolution for the pathologists?].
    Bibeau F; Penault-Llorca F; Sabourin JC
    Ann Pathol; 2008 Sep; 28(4):261-2. PubMed ID: 18928862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.